VU Chenbin (US),ВУ Ченбин (US),GKhAJuR Tarik (US),ГХАЮР Тарик (US),DIKSON Richard V (US),ДИКСОН Ричард В (US),ZAL'FEL'D Jokhen G (US),ЗАЛЬФЕЛЬД Йохен Г (US),VU CHENBIN,ВУ Ченбин,GKHAJUR TARIK,ГХАЮР Тарик,DIKSON RICHARD V,ДИКСОН Ричард В,ZALFELD JOKHEN G,ЗАЛЬФЕЛЬД Йохен Г
申请号：
RU2008110494/10
公开号：
RU0002515108C2
申请日:
2006.08.18
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
FIELD: medicine.SUBSTANCE: claimed invention relates to immunology and biotechnology. Claimed is binding protein for binding one or more targets, which contains four polypeptide chains forming four functional antigen-binding sites. Four polypeptide chains contain VD1-(X1)n-VD2-C-(X2)n. VD1 stands for first variable domain of heavy chain, VD2 stands for second variable domain of heavy chain, C stands for CH1 domain, X1 stands for polypeptide linker, on condition that it is not constant domain, and X2 stands for Fc-region, and n equals 0 or 1. Two polypeptide chains contain VD1-(X1)n-VD2-C. VD1 stands for first variable domain of light chain, VD2 stands for second variable domain of light chain, C stands for CL domain, X1 stands for linker, on condition that it is not constant domain； and n equals 0 or 1. Conjugate of binding protein with visualising detecting cytotoxic or therapeutic agent is described. Disclosed are: nucleic acids (NA), coding polypeptide chains, as well as expressing vectors, vectors for replication, host cells which contain them, and method of obtaining antibody applying cells. Described is pharmaceutical composition for treatment or preventing target-associated disease or disorder based on binding protein. Method of treatment by introduction of binding protein is described.EFFECT: application of invention provides new format (DVD-Ig) of antigen-binding molecules, which in the same dosage possess higher activity with respect to target than respective full-size antibodies, which can be applied in medicine for prevention and treatment of various diseases.45 cl, 27 tbl, 5 exНастоящее изобретение относится к иммунологии и биотехнологии. Предложен связывающий белок для связывания одной или более мишеней, содержащий четыре полипептидные цепи, которые образуют четыре функциональных антигенсвязывающих сайта. Две полипептидные цепи содержат VD1-(X1)n-VD2-С-(Х2)n. VD1 означает первый вариабельный домен тяжелой цепи, VD2 означает второй вариабельный домен
